UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30

Cancer research (Chicago, Ill.), 2014-07, Vol.74 (13), p.3429-3440

2014

Volltextzugriff (PDF)

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

JNCI : Journal of the National Cancer Institute, 2018-06, Vol.110 (6), p.677-681

2018

Volltextzugriff (PDF)

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

The Journal of clinical investigation, 2009-05, Vol.119 (5), p.1251-1263

2009

Volltextzugriff (PDF)

Persister state-directed transitioning and vulnerability in melanoma

Nature communications, 2022-06, Vol.13 (1), p.3055-3055, Article 3055

2022

Volltextzugriff (PDF)

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

Clinical cancer research, 2009-08, Vol.15 (16), p.5208-5215

2009

Volltextzugriff (PDF)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype

Clinical and translational medicine, 2022-11, Vol.12 (11), p.e1090-n/a

2022

Volltextzugriff (PDF)

Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries

PloS one, 2010-11, Vol.5 (11), p.e14137-e14137

2010

Volltextzugriff (PDF)

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma

European journal of cancer (1990), 2016-05, Vol.59, p.109-112

2016

Volltextzugriff (PDF)

Genetic evolution of T-cell resistance in the course of melanoma progression

Clinical cancer research, 2014-12, Vol.20 (24), p.6593-6604

2014

Volltextzugriff (PDF)

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

European journal of cancer (1990), 2021-12, Vol.159, p.113-124

2021

Volltextzugriff (PDF)

Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance

European journal of cell biology, 2014-01, Vol.93 (1-2), p.49-54

2014

Volltextzugriff (PDF)

SF3B1 and BAP1 mutations in blue nevus-like melanoma

Modern pathology, 2017-07, Vol.30 (7), p.928-939

2017

Volltextzugriff (PDF)

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency

Cancer research (Chicago, Ill.), 2016-08, Vol.76 (15), p.4347-4358

2016

Volltextzugriff (PDF)

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma

Investigative ophthalmology & visual science, 2017-07, Vol.58 (9), p.3464-3470

2017

Volltextzugriff (PDF)

Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells

International journal of cancer, 2009-04, Vol.124 (7), p.1594-1604

2009

Volltextzugriff (PDF)

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model

Oncotarget, 2017-04, Vol.8 (17), p.28312-28327

2017

Volltextzugriff (PDF)

MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells

Modern pathology, 2010-04, Vol.23 (4), p.511-521

2010

Volltextzugriff (PDF)

Analysis of SDHD promoter mutations in various types of melanoma

Oncotarget, 2015-09, Vol.6 (28), p.25868-25882

2015

Volltextzugriff (PDF)

Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma

Experimental dermatology, 2003-12, Vol.12 (6), p.799-810

2003

Volltextzugriff (PDF)

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

Clinical cancer research, 2006-06, Vol.12 (11 Pt 1), p.3297-3305

2006

Volltextzugriff (PDF)

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma

Immunology letters, 2000-09, Vol.74 (1), p.67-74

2000

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Aktive Filter

ThemaMelanoma - Pathology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(22)

Sprache

Englisch
(22)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Humans
(22)
Science & Technology
(21)
Life Sciences & Biomedicine
(19)
Melanoma
(15)
Melanoma - Genetics
(13)
Oncology
(12)
Cell Line, Tumor
(9)
Mutation
(9)
Tumors
(9)
Melanoma - Immunology
(8)
Melanoma - Metabolism
(7)
Skin Neoplasms - Pathology
(7)
Neoplasm Metastasis
(6)
Female
(5)
Gene Expression Regulation, Neoplastic
(5)
Male
(5)
Melanoma - Therapy
(5)
Middle Aged
(5)
Skin Neoplasms - Genetics
(5)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metalloprotease-Mediated Tumor Cell Shedding of B7-H6, the Ligand of the Natural Killer Cell-Activating Receptor NKp30

Tumor CDKN2A-Associated JAK2 Loss and Susceptibility to Immunotherapy Resistance

NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo

Persister state-directed transitioning and vulnerability in melanoma

Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype

Screening of human tumor antigens for CD4 T cell epitopes by combination of HLA-transgenic mice, recombinant adenovirus and antigen peptide libraries

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma

Genetic evolution of T-cell resistance in the course of melanoma progression

NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors

Expression of stress ligands of the immunoreceptor NKG2D in melanoma: Regulation and clinical significance

SF3B1 and BAP1 mutations in blue nevus-like melanoma

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency

Frequent GNAQ, GNA11, and EIF1AX Mutations in Iris Melanoma

Interferon‐γ down‐regulates NKG2D ligand expression and impairs the NKG2D‐mediated cytolysis of MHC class I‐deficient melanoma by natural killer cells

HLA class I loss in metachronous metastases prevents continuous T cell recognition of mutated neoantigens in a human melanoma model

MMP19 is upregulated during melanoma progression and increases invasion of melanoma cells

Analysis of SDHD promoter mutations in various types of melanoma

Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma

The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma

Autologous, allogeneic tumor cells or genetically engineered cells as cancer vaccine against melanoma

Aktive Filter

Suchergebnisse filtern